Is there a Bearish outlook for Celldex Therapeutics, Inc. (NASDAQ:CLDX) this week?

January 19, 2018 - By marketbeat

 Is there a Bearish outlook for Celldex Therapeutics, Inc. (NASDAQ:CLDX) this week?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Among 13 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Celldex Therapeutics had 24 analyst reports since August 11, 2015 according to SRatingsIntel. As per Tuesday, June 6, the company rating was maintained by Cowen & Co. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Market Perform” rating given on Monday, March 7 by Leerink Swann. Jefferies downgraded the stock to “Hold” rating in Tuesday, March 8 report. The rating was maintained by Cantor Fitzgerald on Friday, February 26 with “Buy”. On Tuesday, March 8 the stock rating was maintained by H.C. Wainwright with “Buy”. WBB Securities maintained it with “Buy” rating and $10.0 target in Wednesday, December 6 report. The stock has “Neutral” rating by Guggenheim on Monday, March 7. The firm has “Hold” rating given on Tuesday, August 9 by Jefferies. Jefferies maintained it with “Hold” rating and $3.5 target in Thursday, August 31 report. The rating was maintained by Brean Capital with “Buy” on Tuesday, August 11. Below is a list of Celldex Therapeutics, Inc. (NASDAQ:CLDX) latest ratings and price target changes.

06/12/2017 Broker: WBB Securities Rating: Buy New Target: $10.0 Maintain
07/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
12/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $9.0
31/08/2017 Broker: Jefferies Rating: Hold New Target: $3.5 Maintain
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0000 Maintain
01/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10 Reinitiate

The stock decreased 0.72% or $0.02 during the last trading session, reaching $2.74. About 712,430 shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 20.62% since January 19, 2017 and is downtrending. It has underperformed by 37.32% the S&P500.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has market cap of $372.60 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It currently has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

More recent Celldex Therapeutics, Inc. (NASDAQ:CLDX) news were published by: Fool.com which released: “3 Biotech Stocks to Buy in January” on January 03, 2018. Also Fool.com published the news titled: “Will 2018 Be Celldex Therapeutics, Inc.’s Best Year Yet?” on January 16, 2018. Prnewswire.com‘s news article titled: “This Morning’s Technical Outlook on Biotech Stocks — Alnylam Pharma, Celldex …” with publication date: December 27, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: